Allergan
FDA advisory committee approves of Allergan’s night-time urination medicine
October 20, 2016Medical Communications Allergan, FDA, Night-time urination, sleep, urination
The FDA’s advisory committee ruled, in a 14-4 vote, that Allergan’s experimental nocturnal urination medication, SER120, in favour of the …
Nestlé appoints Paul Navarre as CEO of Nestlé Skin Health
October 12, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Nestle skin health, Paul Navarre, nestle
The announcement of Paul Navarre’s appointed as CEO of Nestlé Skin Health was announced on 11 October. He will take …
Teva to sell Allergan’s UK & Ireland generics business for $770m
October 6, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Teva
Teva has announced that it is set to sell Allergan’s UK and Ireland-based generics business for $770 million.
AstraZeneca agrees $250 million licensing agreement with Allergan
October 3, 2016Sales and Marketing Allergan, AstraZeneca, Crohn’s disease, MEDI2070, MedImmune, crohn's disease
Allergan has entered into a licensing agreement with MedImmune, of AstraZeneca, for the global rights of MedI2070, a synthetic antibody. …
Allergan expands NASH portfolio with $1.7 billion in acquisitions
September 21, 2016Research and Development, Sales and Marketing Akarna Therapeutics, Allergan, Tobira Therapeutics, acqusition, nash
Allergan has gone on a spending spree this week, snapping up clinical-stage biotech Tobira Therapeutics and privately-held Akarna Therapeutics for …
Allergan snaps up Vitae Pharma for $639 million
September 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Vitae, acquisition
Allergan has agreed to buy clinical-stage biotech Vitae Pharmaceuticals for $639 million, or $21 a share – more than double …
Allergan CEO outlines ‘social contract with patients’
September 7, 2016Research and Development, Sales and Marketing Allergan, Brent Saunders, CEO, blog
Highlighting a recent shift in the priorities of the pharmaceutical industry, Allergan CEO and president Brent Saunders has outlined a …
Allergan acquires biotech Retrosense for $60 million
September 7, 2016Research and Development, Sales and Marketing Allergan, Retrosense, acquisition
Allergan has announced that it has acquired Retrosense, a biotech focused on novel gene therapy approaches to restore vision in …
Allergan set to acquire eye-care biotech ForSight VISION5
August 12, 2016Medical Communications, Sales and Marketing Allergan, ForSight VISION5, acquisition, biotech, eye care
Allergan has announced its acquisition of privately-held, clinical-stage eye-care biotech ForSight VISION5 for a $95 million upfront payment and a …
Takeover rumours send Biogen’s stock soaring
August 3, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Biogen, MSD, rumours, takeover
Rumours have begun to circulate that companies including MSD and Allergan are plotting a takeover bid for Biogen, after a …
Teva completes $40 billion acquisition of Actavis Generics
August 3, 2016Research and Development, Sales and Marketing Actavis, Allergan, Teva, acqusition, generics
Teva has announced that it has completed its acquisition of Actavis Generics, a subsidiary of Allergan, in a transaction valued …
IBS-D treatment Truberzi receives positive opinion from CHMP
July 26, 2016Manufacturing and Production, Sales and Marketing Allergan, EU, Truberzi, diarrhoea. CHMP, irritable bowel syndrome
Global pharmaceutical company Allergan has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of …
Phase III study confirms similarity of Herceptin biosimilar from Amgen, Allergan
July 22, 2016Medical Communications, Research and Development Allergan, Amgen, Herceptin, Roche, biosimilar, trastuzumab
Amgen and Allergan have announced the results from a Phase III study investigating ABP 980, their biosimilar candidate for Roche’s …
Teva sells $15 billion in bonds to fund Allergan generics deal
July 19, 2016Manufacturing and Production, Sales and Marketing Allergan, Teva, bonds, generics
Teva Pharmaceuticals has announced that it has successfully finalised a bond sale totalling $15 billion that will help to fund …
Teva looking at up to $25 billion in bond sale to fund Allergan’s generic-unit buy – reports
July 15, 2016Medical Communications, Sales and Marketing Allergan, Financial, Teva, US regulators, bond sale, deal
Israeli drug firm Teva (NYSE: TEVA) is looking at a $20 billion to $25 billion bond sale in the US …
Latest content
FibroFind appoints Lee Borthwick as CEO
